Swedbank AB Buys 1,897 Shares of Becton, Dickinson and Company $BDX

Key Points

• Swedbank AB increased its stake in Becton, Dickinson and Company by 1.2%, now owning approximately 154,190 shares valued at $35.3 million.
• Insider selling includes Director Claire Fraser and EVP Michael David Garrison, with significant decreases in their ownership post-sale.
• Becton, Dickinson and Company reported a 10.4% year-over-year increase in quarterly revenue, totaling $5.51 billion, and exceeded EPS estimates with a reported $3.68.

Swedbank AB raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,190 shares of the medical instruments supplier's stock after purchasing an additional 1,897 shares during the period. Swedbank AB owned approximately 0.05% of Becton, Dickinson and Company worth $35,319,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BDX. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $27,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 99 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 0.3%

NYSE BDX traded up $0.51 on Tuesday, reaching $186.25. The company had a trading volume of 1,211,488 shares, compared to its average volume of 2,562,473. The firm has a market cap of $53.38 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business has a 50 day moving average of $186.72 and a two-hundred day moving average of $190.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,965 shares of company stock valued at $551,536. Company insiders own 0.36% of the company's stock.

Analysts Set New Price Targets

BDX has been the subject of several research analyst reports. Barclays lowered their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price target for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Piper Sandler restated a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.